...
search icon
crvs-img

Corvus Pharmaceuticals Inc Share Price

CRVS
NMQ
$17.49
-$1.17
(-6.27%)
1D
Industry: Biotechnology Sector: Health Care

Corvus Pharmaceuticals Inc Analyst Forecast

Corvus Pharmaceuticals Inc Share Price Chart

Corvus Pharmaceuticals Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.56B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.65M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.75
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.54 L
$26.95 H
$17.49

About Corvus Pharmaceuticals Inc, Common Stock

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Corvus Pharmaceuticals Inc Stock Returns

Time FrameCRVSSectorS&P500
1-Week Return-10.73%1.51%-1.5%
1-Month Return-18.36%1.46%0.6%
3-Month Return96.18%3.94%2.43%
6-Month Return228.57%16.03%6.01%
1-Year Return266.46%9.1%11.48%
3-Year Return2230.67%19.46%67.52%
5-Year Return385.56%35.29%73.75%
10-Year Return22.67%137.42%254.46%

Corvus Pharmaceuticals Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue632.00K460.00K367.00K151.00K85.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":72.78,"profit":true},{"date":"2022-12-31","value":58.07,"profit":true},{"date":"2023-12-31","value":23.89,"profit":true},{"date":"2024-12-31","value":13.45,"profit":true}]
Gross Profit(632.00K)(460.00K)(367.00K)(151.00K)(85.00K)[{"date":"2020-12-31","value":-63200000,"profit":false},{"date":"2021-12-31","value":-46000000,"profit":false},{"date":"2022-12-31","value":-36700000,"profit":false},{"date":"2023-12-31","value":-15100000,"profit":false},{"date":"2024-12-31","value":-8500000,"profit":false}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses43.76M38.63M32.56M23.41M27.55M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":88.28,"profit":true},{"date":"2022-12-31","value":74.42,"profit":true},{"date":"2023-12-31","value":53.49,"profit":true},{"date":"2024-12-31","value":62.95,"profit":true}]
Operating Income(43.76M)(38.63M)(32.56M)(23.41M)(27.55M)[{"date":"2020-12-31","value":-4376000000,"profit":false},{"date":"2021-12-31","value":-3863000000,"profit":false},{"date":"2022-12-31","value":-3256500000,"profit":false},{"date":"2023-12-31","value":-2340700000,"profit":false},{"date":"2024-12-31","value":-2754800000,"profit":false}]
Total Non-Operating Income/Expense38.30M(4.63M)(8.09M)(2.10M)(32.92M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-12.08,"profit":false},{"date":"2022-12-31","value":-21.11,"profit":false},{"date":"2023-12-31","value":-5.48,"profit":false},{"date":"2024-12-31","value":-85.94,"profit":false}]
Pre-Tax Income(6.00M)(43.24M)(41.31M)(27.03M)(62.29M)[{"date":"2020-12-31","value":-599500000,"profit":false},{"date":"2021-12-31","value":-4324100000,"profit":false},{"date":"2022-12-31","value":-4130700000,"profit":false},{"date":"2023-12-31","value":-2702900000,"profit":false},{"date":"2024-12-31","value":-6229300000,"profit":false}]
Income Taxes(1.17M)(5.04M)8.74M--[{"date":"2020-12-31","value":-13.41,"profit":false},{"date":"2021-12-31","value":-57.66,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(4.82M)(38.20M)(50.05M)--[{"date":"2020-12-31","value":-482300000,"profit":false},{"date":"2021-12-31","value":-3820000000,"profit":false},{"date":"2022-12-31","value":-5004900000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(6.00M)(43.24M)(41.31M)(30.19M)(62.29M)[{"date":"2020-12-31","value":-599500000,"profit":false},{"date":"2021-12-31","value":-4324100000,"profit":false},{"date":"2022-12-31","value":-4130700000,"profit":false},{"date":"2023-12-31","value":-3019200000,"profit":false},{"date":"2024-12-31","value":-6229300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(4.82M)(43.24M)(41.31M)(27.03M)(62.29M)[{"date":"2020-12-31","value":-482300000,"profit":false},{"date":"2021-12-31","value":-4324100000,"profit":false},{"date":"2022-12-31","value":-4130700000,"profit":false},{"date":"2023-12-31","value":-2702900000,"profit":false},{"date":"2024-12-31","value":-6229300000,"profit":false}]
EPS (Diluted)(1.46)(1.06)(0.89)(0.57)(0.90)[{"date":"2020-12-31","value":-146,"profit":false},{"date":"2021-12-31","value":-106,"profit":false},{"date":"2022-12-31","value":-89,"profit":false},{"date":"2023-12-31","value":-57,"profit":false},{"date":"2024-12-31","value":-90.29,"profit":false}]

Corvus Pharmaceuticals Inc Ratios

Corvus Pharmaceuticals Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

CRVS
Cash Ratio 8.14
Current Ratio 8.29

Corvus Pharmaceuticals Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CRVS
ROA (LTM) -34.87%
ROE (LTM) -35.82%

Corvus Pharmaceuticals Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CRVS
Debt Ratio Lower is generally better. Negative is bad. 0.11
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.89

Corvus Pharmaceuticals Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CRVS
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 21.78
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.36
PEG NM

FAQs

What is Corvus Pharmaceuticals Inc share price today?

Corvus Pharmaceuticals Inc (CRVS) share price today is $17.49

Can Indians buy Corvus Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Corvus Pharmaceuticals Inc (CRVS) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRVS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Corvus Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Corvus Pharmaceuticals Inc (CRVS) via the Vested app. You can start investing in Corvus Pharmaceuticals Inc (CRVS) with a minimum investment of $1.

How to invest in Corvus Pharmaceuticals Inc shares from India?

You can invest in shares of Corvus Pharmaceuticals Inc (CRVS) via Vested in three simple steps:

  • Click on Sign Up or Invest in CRVS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Corvus Pharmaceuticals Inc shares
What is Corvus Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Corvus Pharmaceuticals Inc (CRVS) is $26.95. The 52-week low price of Corvus Pharmaceuticals Inc (CRVS) is $2.54.

What is Corvus Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Corvus Pharmaceuticals Inc (CRVS) is

What is Corvus Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Corvus Pharmaceuticals Inc (CRVS) is 21.78

What is Corvus Pharmaceuticals Inc dividend yield?

The dividend yield of Corvus Pharmaceuticals Inc (CRVS) is 0.00%

What is the Market Cap of Corvus Pharmaceuticals Inc?

The market capitalization of Corvus Pharmaceuticals Inc (CRVS) is $1.56B

What is Corvus Pharmaceuticals Inc's stock symbol?

The stock symbol (or ticker) of Corvus Pharmaceuticals Inc is CRVS

How Can Investors Use Corvus Pharmaceuticals Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Corvus Pharmaceuticals Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Corvus Pharmaceuticals Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Corvus Pharmaceuticals Inc shares for Indian investors?

When investing in Corvus Pharmaceuticals Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Corvus Pharmaceuticals Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Corvus Pharmaceuticals Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Corvus Pharmaceuticals Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Corvus Pharmaceuticals Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top